Back to Annual Meeting Page
133rd Annual Meeting & Exposition
December 10-14, 2005
Philadelphia, PA
|
Back to Annual Meeting Page
|
133rd Annual Meeting & Exposition December 10-14, 2005 Philadelphia, PA |
|
|
5104.0: Wednesday, December 14, 2005: 12:30 PM-2:00 PM | |||
Oral | |||
| |||
| In this session the learner will hear about tuberculosis, including the suspected spread of the disease within a university setting and a population-based study of the risk factors among drug users who have tuberculosis. | |||
| Learning Objectives: At the conclusion of the session, the participant (learner) in this session will be able to: 1. Make sound communicable disease response decisions using quantifiable outcomes and reliable science. 2. Describe LPHA response measures in context of scenario 3. Identify the value and limits of field epidemiology to guide tuberculosis control decisions 4. Describe the sociodemographic, behavioral, and clinical characteristics of self-reported drug users with tuberculosis 5. To demonstrate that AEs often result in non-adherence due to treatment interruptions. | |||
| Julie Franks, PhD | |||
Suspected widespread tuberculosis exposure within a university setting; an extensive case-contact investigation and response by Local Public Health Agency (LPHA) in Milwaukee, WI ![[ Recorded presentation ]](/static/img/filetypes/16x16/wrf.gif){kind=small} Geoffrey R. Swain, MD, MPH, Paul Biedrzycki, MPH, MBA, Angela M. Hagy, MSPH, Irmine Reitl, RN, MSN, David Campbell, BS RS, Douglas Gieryn, BS, RS, Frederick A. Radmer, MPH | |||
| In search of evidence-based tuberculosis control: Identifying the work-place contacts to an office worker who developed multi-drug resistant tuberculosis Alicia Paris-Pombo, MD, MS, Kim Smith, PHN, MSN, Richard Tezak, MD, MPH, Hugh Stallworth, MD, MPH | |||
| A population-based study of the risk factors among drug users who have tuberculosis in Houston, Texas Paige L. Bordelon, MPH, James M. Musser, MD, PhD, Edward A. Graviss, PhD, MPH | |||
| Patient reporting of adverse events during isoniazid treatment of latent tuberculosis infection R. Margaret Whelan, Julie Franks, PhD, Nancy Holson, MPH, Sharon B. Mannheimer, MD, Yael Hirsch-Moverman, MPH, Wafaa El-Sadr, MD | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Organized by: | Epidemiology | ||
| CE Credits: | CME, Health Education (CHES), Nursing | ||
The 133rd Annual Meeting & Exposition (December 10-14, 2005) of APHA